Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology
Do you routinely send Oncotype Dx on ER positive tumors with node positive disease?
If so, how do you counsel patients who are node positive with low or intermediate risk scores? How do you interpret the existing data? NCCN and ASCO guidelines are conflicting.
Answer from: Medical Oncologist at Academic Institution
I believe that the intrinsic biology of the tumor is more important than the lymph node status in determining prognosis and potential chemotherapy benefit. Given this, I do use molecular assays for node positive disease with caution. Based on a 2010 Lancet Oncology paper in which tissue blocks from ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
There's no such thing as routinely ordering genomic assays - it is just bad clinical practice. Ask two questions before you consider ordering any genomic assays for breast cancer.
1. Will this patient tolerate chemotherapy - If answer is NO, do not order genomic tests.
2. Has the patient stated ve...